Skip to content

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined with Genetic and Molecular Diagnostics: A Prospective Observational Study

Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined with Genetic and Molecular Diagnostics: A Prospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116115
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Micropapillary thyroid carcinoma

Interventions

Gold Standard:Postoperative pathological findings
Index test:Indicators of ablation lesion uptake or surgical removal of the original thyroid area, ultrasonography of the cervical lymph nodes, laboratory tests, postoperative adverse effects, local re

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 18-70 years old, gender is not limited; 2. Low-risk PTMC patients on initial treatment (meeting all of the following criteria: single lesion with a maximum diameter of <=1 cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal invasion no family history of thyroid cancer; no history of head and neck radiation during childhood); 3. The patient has received preoperative fine-needle aspiration cytology of thyroid nodules and 88-gene test for thyroid cancer; 4. Patients volunteered to undergo microwave ablation or surgical resection;

Exclusion criteria

Exclusion criteria: 1. Tumor located in the isthmus of the thyroid gland; 2. Pathologic high-risk subtypes (hypercellular subtype, columnar cell subtype, diffuse sclerotic type, solid/islet type, eosinophilic subtype); 3. Progressive short-term enlargement of the cancer foci (more than 3 mm in 6 months); 4. Pregnant and lactating women; 5. Patients with severe coagulation disorders; 6. The patient has contralateral vocal cord dysfunction; 7. patients with contraindications to ultrasound contrast agents; 8. Other conditions that, in the judgment of the investigator, do not meet the enrollment requirements.

Design outcomes

Primary

MeasureTime frame
Evaluation of efficacy;

Countries

China

Contacts

Public ContactQiyun Ou

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

oeven@foxmail.com+86 20 34071020

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026